Dr. Harshman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 1230
Boston, MA 02215Phone+1 617-632-4524
Education & Training
Stanford Health CareFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2003 - 2006
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2003
Certifications & Licensure
CA State Medical License 2006 - Present
FL State Medical License 2023 - 2025
MA State Medical License 2012 - 2021- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Start of enrollment: 2009 Oct 01
- Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2014 Aug 01
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Start of enrollment: 2017 Apr 28
- Join now to see all
Publications & Presentations
PubMed
- 143 citationsThe Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma PatientsPhilip S. Hall, Lauren C. Harshman, Sandy Srinivas, Ronald M. Witteles
JACC. Heart Failure. 2013-02-01 - 112 citationsTime of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).Edoardo Francini, Kathryn P. Gray, Wanling Xie, Grace Shaw, Loana B Valenca
The Prostate. 2018-09-01 - 64 citationsElevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resis...Jaya Sharma, Kathryn P. Gray, Lauren C. Harshman, Carolyn Evan, Mari Nakabayashi
The Prostate. 2014-06-01
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Lectures
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (E...2019 ASCO Annual Meeting - 6/1/2019
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrec...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- 13th Multidisciplinary Management of Cancers: A Case-based ApproachStanford Hospital & Clinic, Stanford, California - 3/9/2012
Press Mentions
The Combination of Pembrolizumab and Radium-223 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Atish ChouduryFebruary 26th, 2021
Activity of Cabozantinib in Advanced Non–Clear Cell Renal Cell CarcinomaMarch 15th, 2019
Cabozantinib Active Across Non-Clear Cell Kidney CancersMarch 6th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
